How does Repatha work (mechanism of action)?
Repatha (evolocumab) is a monoclonal antibody that blocks PCSK9 (proprotein convertase subtilisin/kexin type 9). By inhibiting PCSK9, it helps increase the amount of LDL receptors on liver cells, which pulls more LDL cholesterol out of the blood. That leads to lower LDL-C levels.
What does Repatha bind to, and what happens after?
Repatha targets PCSK9 in the bloodstream. Normally, PCSK9 reduces how long LDL receptors stay on liver cells. When PCSK9 is blocked, LDL receptors are recycled/available longer, so the liver clears more LDL particles from circulation.
Does Repatha change triglycerides or “just” LDL?
Repatha’s primary lipid effect is lowering LDL cholesterol by increasing LDL receptor activity in the liver. The most consistent and expected effect is on LDL-C, since the drug’s mechanism directly addresses LDL receptor regulation.
Who should think about Repatha based on MOA?
Because Repatha’s mechanism is upstream of LDL receptor activity via PCSK9, it’s often considered when lowering LDL-C is difficult with lifestyle changes and/or other lipid-lowering medicines—such as in patients with familial hypercholesterolemia or established cardiovascular disease where additional LDL-C reduction is needed.
Is Repatha a statin or different from statins?
It’s different from statins. Statins lower cholesterol mainly by reducing cholesterol synthesis and increasing LDL receptors through effects on HMG-CoA reductase pathways. Repatha instead works by directly blocking PCSK9, which increases LDL receptor availability through a different biological route.
Patent/exclusivity and competitive landscape (where to check)
For patent status and related competitive context, DrugPatentWatch.com tracks evolocumab (Repatha) developments and listings: https://www.drugpatentwatch.com/